Omeros Set for Potential Breakout Ahead of FDA Decision
AI Prediction of Omeros Corporation (OMER)
Omeros, with its significant clinical developments and recent financial restructuring, appears poised for potential growth. The expected FDA decisions and advancements in clinical trials for narsoplimab and other pipeline assets could serve as significant catalysts for stock price movement.
OMER Report Information
Prediction Date2025-07-03
Close @ Prediction$3.20
Mkt Cap970m
IPO DateN/a
AI-derived Information
Recent News for OMER
- Apr 16, 8:45 am — CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA (narsoplimab-wuug) (Business Wire)
- Apr 10, 8:11 pm — Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect? (Quartz)
- Apr 1, 8:30 am — Omeros Corporation Q4 2025 Earnings Call Summary (Moby)
- Mar 31, 11:02 pm — Omeros Corp (OMER) Q4 2025 Earnings Call Highlights: A Turnaround with Strategic Deals and FDA ... (GuruFocus.com)
- Mar 31, 4:22 pm — Omeros: Q4 Earnings Snapshot (Associated Press)
- Mar 31, 4:02 pm — Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results (Business Wire)
- Mar 26, 8:45 am — Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 (Business Wire)
- Mar 21, 3:23 am — Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment (Business Wire)
- Feb 17, 8:45 am — Omeros Announces Successful Primate Study in OncotoX-AML Drug Program (Business Wire)
- Jan 27, 9:00 am — Omeros Announces First Commercial Sales of YARTEMLEA (Business Wire)
- Dec 29, 10:57 am — Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA (Zacks)
- Dec 26, 6:36 pm — Omeros Announces New Date for YARTEMLEA Approval Conference Call (Business Wire)
NDAPR (News-Driven AI Prediction Revision) events for OMER
-
Mar 31, 7:19 pmRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason:Rationale: Catalyst progress.
-
Mar 26, 9:18 amRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason:Rationale: No new information impacts the original prediction or investment thesis.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Well, today OMER had a major breakthrough, and surpassed the predicted high, but about 5 days late. This could be partly due to the government shutdown.